Abstract
STUDY OBJECTIVE: To examine the relation between experimental and non- experimental study design in vaccinology. DESIGN: Assessment of each study design's capability of testing four aspects of vaccine performance, namely immunogenicity (the capacity to stimulate the immune system), duration of immunity conferred, incidence and seriousness of side effects, and number of infections prevented by vaccination. SETTING: Experimental and non-experimental studies on hepatitis B (HB) vaccines in the Cochrane Vaccines Field Database. RESULTS: Experimental and non-experimental vaccine study designs are frequently complementary but some aspects of vaccine quality can only be assessed by one of the types of study. More work needs to be done on the relation between study quality and its significance in terms of effect size.
Full Text
The Full Text of this article is available as a PDF (93.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baudrihaye N. European Vaccine Manufacturers: present status and future trends. Vaccine. 1992;10(13):893–895. doi: 10.1016/0264-410x(92)90319-f. [DOI] [PubMed] [Google Scholar]
- Bell A. Universal hepatitis B immunization: the British Columbia experience. Vaccine. 1995;13 (Suppl 1):S77–S81. doi: 10.1016/0264-410x(95)80061-h. [DOI] [PubMed] [Google Scholar]
- Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996 May 11;312(7040):1215–1218. doi: 10.1136/bmj.312.7040.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Doebbeling B. N., Ferguson K. J., Kohout F. J. Predictors of hepatitis B vaccine acceptance in health care workers. Med Care. 1996 Jan;34(1):58–72. doi: 10.1097/00005650-199601000-00005. [DOI] [PubMed] [Google Scholar]
- Jefferson T., Jefferson V. The quest for trials on the efficacy of human vaccines. Results of the handsearch of Vaccine. Vaccine. 1996 Apr;14(6):461–464. doi: 10.1016/0264-410x(95)00247-x. [DOI] [PubMed] [Google Scholar]
- Jefferson T. New and not so new vaccines. BMJ. 1996 Sep 28;313(7060):768–768. doi: 10.1136/bmj.313.7060.768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kane M. A. Global status of hepatitis B immunisation. Lancet. 1996 Sep 14;348(9029):696–696. doi: 10.1016/S0140-6736(05)65598-5. [DOI] [PubMed] [Google Scholar]
- Schulz K. F., Chalmers I., Hayes R. J., Altman D. G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 Feb 1;273(5):408–412. doi: 10.1001/jama.273.5.408. [DOI] [PubMed] [Google Scholar]
- Wood R. C., MacDonald K. L., White K. E., Hedberg C. W., Hanson M., Osterholm M. T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA. 1993 Dec 22;270(24):2935–2939. [PubMed] [Google Scholar]